tiprankstipranks
Exelixis names Dana Aftab next chief scientific officer
The Fly

Exelixis names Dana Aftab next chief scientific officer

According to a regulatory filing, Exelixis said that Peter Lamb, Ph.D., currently, Executive Vice President, Scientific Strategy and Chief Scientific Officer of Exelixis, will transition into a new role as Executive Vice President, Scientific Strategy, effective as of Thursday. Dana T. Aftab, Ph.D., will become the company’s next Chief Scientific Officer and will also serve as Executive Vice President, Discovery and Translational Research. Aftab received his Ph.D. in Pharmacology from Yale University and did postdoctoral research in oncogene signaling at the University of California, Berkeley. Aftab has been with Exelixis for over 24 years serving in various roles of increasing responsibility, beginning in Exelixis’ Drug Discovery organization, where he led teams that drove the discovery and development of the company’s approved medicines including cabozantinib, to a role as Senior Vice President, Translational Research, leading an effort that streamlined the company’s processes for transitioning drug discovery programs into clinical development. Most recently, Aftab served as Executive Vice President, Business Operations.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on EXEL:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles